Analysed PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) News Sources
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
13-04-2026
yahoo.com
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
06-04-2026
yahoo.com
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine
05-04-2026
yahoo.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
30-03-2026
yahoo.com
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
18-03-2026
fool.com
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization?
18-03-2026
yahoo.com
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway
18-03-2026
yahoo.com
What is the current price of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The current price of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is $331.01.
PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) since the previous trading day is $14.87.
PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) since the previous trading day is 4.7036%.
What is the most recent average sentiment score for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The most recent average sentiment score for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The most recent sentiment for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is .
SEC-8K** Filing Available For PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.